ong-term follow up of patients in European Vasculitis Study Group clinical trials

Not Applicable

Completed

• Conditions: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA, Wegener’s granulomatosis (WG)) or microscopic polyangiitis (MPA); Other necrotizing vasculopathies; Circulatory System

• Registration Number: ISRCTN52952998
• Lead Sponsor: Skane University Hospital Malmö-Lund, Sweden

Brief Summary

1. 2011 results in: http://www.ncbi.nlm.nih.gov/pubmed/21109517 2. 2011 results in: http://www.ncbi.nlm.nih.gov/pubmed/21156667 3. 2011 results in: http://www.ncbi.nlm.nih.gov/pubmed/21890618 4. 2011 results in: http://www.ncbi.nlm.nih.gov/pubmed/21452269 5. 2011 results in: http://www.ncbi.nlm.nih.gov/pubmed/21616914 6. 2012 results in: http://www.ncbi.nlm.nih.gov/pubmed/22614882 7. 2012 results in: http://www.ncbi.nlm.nih.gov/pubmed/21953279 8. 2012 results in: http://www.ncbi.nlm.nih.gov/pubmed/22128076 9. 2013 results in: http://www.ncbi.nlm.nih.gov/pubmed/23615499 10. 2013 results in: http://www.ncbi.nlm.nih.gov/pubmed/22962314 11. 2013 results in: http://www.ncbi.nlm.nih.gov/pubmed/23380137 12. 2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/26016754 13. 2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/25601266 14. 2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/25205825 15. 2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/24243925 16. 2016 results in: http://www.ncbi.nlm.nih.gov/pubmed/27973575 17. 2017 results in: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1321-1 18. 2017 results in: http://www.ncbi.nlm.nih.gov/pubmed/28053275

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-05-07
• Study Completion: 2019-12-31
• Last Update Posted: 30 March 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 875

Inclusion Criteria

Current participant inclusion criteria as of 11/07/2019:
1. Patients with newly diagnosed Anti-Neutrophil Cytoplasm Antibody Vasculitis recruited into one of EUVAS’ randomized controlled trials, NORAM, CYCAZAREM, MEPEX, CYCLOPS, RITUXVAS, IMPROVE, MYCYC performed by European Vasculitis Society (EUVAS)

Previous participant inclusion criteria:
1. Patients with newly diagnosed Anti-Neutrophil Cytoplasm Antibody Vasculitis recruited into one of four randomised controlled trials, NORAM, CYCAZAREM, MEPEX, CYCLOPS performed by European Vasculitis Study Group
2. The patients were recruited during the period of 1995 to 2002

Exclusion Criteria

1. Patients withdrawn from original study due to incorrect diagnosis
2. Consent withheld by patient

Study & Design

• Study Type: Observational
• Study Design: Not specified